{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:19:05Z","timestamp":1787671145437,"version":"build-2736575974"},"reference-count":475,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.yebeh.2022.108693","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T12:27:15Z","timestamp":1650889635000},"page":"108693","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"PA","title":["Movement disorders associated with antiseizure medications: A systematic review"],"prefix":"10.1016","volume":"131","author":[{"given":"Daniel J.","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spriha","family":"Pavuluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Snehal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Situ-Kcomt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Taraschenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2022.108693_b0005","first-page":"31","article-title":"Varying uses of anticonvulsant medications","volume":"5","author":"Cascade","year":"2008","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.yebeh.2022.108693_b0010","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.seizure.2007.12.003","article-title":"Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies","volume":"17","author":"Zaccara","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b0015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1684\/j.1950-6945.2004.tb00064.x","article-title":"Adverse motor effects induced by antiepileptic drugs","volume":"6","author":"Zaccara","year":"2004","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b0020","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1212\/01.WNL.0000123695.22623.32","volume":"62","author":"French","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b0025","doi-asserted-by":"crossref","unstructured":"Panayiotopoulos CP, Benbadis SR, Covanis A, Dulac O, Duncan JS, Eeg-Olofsson O, et al. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2005;64:172,4; author reply 172.","DOI":"10.1212\/WNL.64.1.172"},{"key":"10.1016\/j.yebeh.2022.108693_b0030","unstructured":"Sills G. Mechanisms of action of antiepileptic drugs. In: Sander JW, Walker MC, Smalls JE, editors. From science to society. A practical guide to epilepsy. London, UK: ILAE (UK Chapter) and the National Society for Epilepsy; 2011. p. Chapter 25."},{"key":"10.1016\/j.yebeh.2022.108693_b0035","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1152\/jn.00378.2010","article-title":"Mechanisms of sustained high firing rates in two classes of vestibular nucleus neurons: Differential contributions of resurgent na, Kv3, and BK currents","volume":"104","author":"Gittis","year":"2010","journal-title":"J Neurophysiol"},{"key":"10.1016\/j.yebeh.2022.108693_b0040","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/01.jcp.0000219927.49799.c0","article-title":"Combination therapy of lamotrigine and escitalopram may cause myoclonus","volume":"26","author":"Rosenhagen","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0045","doi-asserted-by":"crossref","unstructured":"Yitzhak S, Krivoy N. Safety and efficacy of lamotrigine in older adults with epilepsy and co-morbid depressive symptoms. Clin Med Insights: Ther 2009;1.https:\/\/doi.org\/10.4137\/CMT.S2165.","DOI":"10.4137\/CMT.S2165"},{"key":"10.1016\/j.yebeh.2022.108693_b0050","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2125.2005.02529.x","article-title":"Clinically relevant drug interactions with antiepileptic drugs","volume":"61","author":"Perucca","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.yebeh.2022.108693_b0060","unstructured":"Zhou D, Schmidt C, Taraschenko O. Movement disorders associated with anticonvulsants: a systematic review. PROSPERO 2021. CRD42021242850."},{"key":"10.1016\/j.yebeh.2022.108693_b0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042098611411127","article-title":"New generation antiepileptic drugs: What do they offer in terms of improved tolerability and safety?","volume":"2","author":"French","year":"2011","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.yebeh.2022.108693_b0070","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","article-title":"30 years of second-generation antiseizure medications: Impact and future perspectives","volume":"19","author":"Perucca","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0075","series-title":"Disorders of movement: A guide to diagnosis and treatment","author":"Martino","year":"2016"},{"key":"10.1016\/j.yebeh.2022.108693_b0080","series-title":"Eye movement disorders","author":"Wong","year":"2008"},{"key":"10.1016\/j.yebeh.2022.108693_b0085","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/bmjebm-2017-110853","article-title":"Methodological quality and synthesis of case series and case reports","volume":"23","author":"Murad","year":"2018","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.yebeh.2022.108693_b0090","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2022.108693_b0095","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.yebeh.2022.108693_b0100","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1177\/070674378603100507","article-title":"Anticonvulsant medications: An iatrogenic cause of tic disorders","volume":"31","author":"Burd","year":"1986","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b0105","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/000992289203100413","article-title":"Report of a case of phenobarbital-induced dystonia","volume":"31","author":"Lacayo","year":"1992","journal-title":"Clin Pediatr"},{"key":"10.1016\/j.yebeh.2022.108693_b0110","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/pgmj.54.628.114","article-title":"Phenobarbital dyskinesia","volume":"54","author":"Lightman","year":"1978","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b0115","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/0887-8994(86)90042-1","article-title":"Phenobarbital-induced tourette-like symptoms","volume":"2","author":"Sandyk","year":"1986","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0120","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000116250","article-title":"Phenobarbital-induced buccolingual dyskinesia in oral apraxia","volume":"28","author":"Sechi","year":"1988","journal-title":"Eur Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0125","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1212\/WNL.34.12.1600","article-title":"Phenobarbital-induced dyskinesia in a neurologically-impaired child","volume":"34","author":"Wiznitzer","year":"1984","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b0130","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1136\/jnnp.39.12.1210","article-title":"Anticonvulsant induced dyskinesias: A comparison with dyskinesias induced by neuroleptics","volume":"39","author":"Chadwick","year":"1976","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b0135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.seizure.2019.06.012","article-title":"Efficacy of phenobarbital and sodium valproate in treating convulsive epilepsy in rural Northeast China","volume":"71","author":"Li","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b0140","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.yebeh.2015.11.007","article-title":"A preliminary observation of the adverse effects of phenobarbital among patients with convulsive epilepsy in rural West China","volume":"54","author":"Si","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b0145","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0022-510X(82)90128-9","article-title":"Truncal ataxia in chronic anticonvulsant treatment. Association with drug-induced folate deficiency","volume":"55","author":"Mu\u00f1oz-Garcia","year":"1982","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2022.108693_b0150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.24953\/turkjped.2018.01.019","article-title":"Phenytoin induced dystonia","volume":"60","author":"Acar","year":"2018","journal-title":"Turk J Pediatr"},{"key":"10.1016\/j.yebeh.2022.108693_b0155","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/jnnp.38.3.225","article-title":"Involuntary movements caused by phenytoin intoxication in epileptic patients","volume":"38","author":"Ahmad","year":"1975","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b0160","doi-asserted-by":"crossref","first-page":"96","DOI":"10.14581\/jer.20016","article-title":"Irreversible cerebellar atrophy as a complication of short-term phenytoin exposure: Clinical improvement following discontinuation of the culprit","volume":"10","author":"Algahtani","year":"2020","journal-title":"J Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b0165","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ana.410040516","article-title":"Downbeat nystagmus due to anticonvulsant toxicity","volume":"4","author":"Alpert","year":"1978","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0170","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4103\/0028-3886.76864","article-title":"Refractory hiccups due to phenytoin therapy","volume":"59","author":"Asadi-Pooya","year":"2011","journal-title":"Neurol India"},{"key":"10.1016\/j.yebeh.2022.108693_b0175","doi-asserted-by":"crossref","first-page":"731","DOI":"10.4103\/0253-7613.89839","article-title":"Phenytoin induced chorea in a pediatric patient: An interaction between phenytoin, phenobarbital and clobazam","volume":"43","author":"Barvaliya","year":"2011","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0180","first-page":"209","article-title":"Downbeat nystagmus with phenytoin","volume":"2","author":"Berger","year":"1982","journal-title":"J Clin Neuro-Ophthalmol"},{"key":"10.1016\/j.yebeh.2022.108693_b0185","first-page":"102","article-title":"Phenytoin toxicity and thyroid dysfunction","volume":"122","author":"Betteridge","year":"2009","journal-title":"New Zealand Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b0190","first-page":"105","article-title":"Athetosis and phenytoin toxicity","volume":"131","author":"Buchanan","year":"1977","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.yebeh.2022.108693_b0195","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/08830738030180070101","article-title":"Use of biperiden hydrochloride in a child with severe dyskinesia induced by phenytoin","volume":"18","author":"Caksen","year":"2003","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0200","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0022-3476(76)80956-0","article-title":"Letter: Phenytoin-induced choreoathetosis","volume":"89","author":"Chalhub","year":"1976","journal-title":"J Pediatr"},{"key":"10.1016\/j.yebeh.2022.108693_b0205","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1212\/WNL.26.5.494","article-title":"Phenytoin induced dystonia and choreoathetosis in two retarded epileptic children","volume":"26","author":"Chalhub","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b0210","first-page":"274","article-title":"Phenytoin induced dyskinesia","volume":"35","author":"Chaudhary","year":"1998","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.yebeh.2022.108693_b0215","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/026990500421949","article-title":"Phenytoin-induced asterixis - uncommon or under-diagnozed?","volume":"14","author":"Chi","year":"2000","journal-title":"Brain Inj"},{"key":"10.1016\/j.yebeh.2022.108693_b0220","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1469-8749.1984.tb04510.x","article-title":"Focal dystonic reaction to phenytoin","volume":"26","author":"Choonara","year":"1984","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0225","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/ana.410140120","article-title":"Phenytoin-induced dystonia","volume":"14","author":"Corey","year":"1983","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0230","first-page":"5","article-title":"A case report on phenytoin induced ataxia","volume":"9","author":"Dasari","year":"2016","journal-title":"Asian J Pharm Clin Res"},{"key":"10.1016\/j.yebeh.2022.108693_b0235","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/tpj.2012.19","article-title":"Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: Influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms","volume":"13","author":"Dorado","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.yebeh.2022.108693_b0240","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/00002826-199619060-00009","article-title":"Postural myoclonus induced by phenytoin","volume":"19","author":"Duarte","year":"1996","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0245","first-page":"981","article-title":"Phenytoin-induced parkinsonism","volume":"47","author":"Ertan","year":"2006","journal-title":"Singapore Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b0250","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0022-3476(87)80570-X","article-title":"Transient chorea induced by phenytoin","volume":"110","author":"Filloux","year":"1987","journal-title":"J Pediatr"},{"key":"10.1016\/j.yebeh.2022.108693_b0255","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1002\/ccr3.1870","article-title":"Phenytoin-induced choreoathetosis after serial seizures due to traumatic brain injury and chronic alcoholism","volume":"6","author":"Finsterer","year":"2018","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.yebeh.2022.108693_b0260","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000000562","article-title":"Phenytoin induced chorea: A case report","volume":"25","author":"Gill","year":"2018","journal-title":"Am J Ther"},{"key":"10.1016\/j.yebeh.2022.108693_b0265","first-page":"1449","article-title":"Paroxysmal dyskinesia in phenytoin toxicity","volume":"50","author":"Girija","year":"2002","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.yebeh.2022.108693_b0270","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00002826-198512000-00012","article-title":"Parkinsonism induced by phenytoin","volume":"8","author":"Go\u00f1i","year":"1985","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0275","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/WNF.0000000000000140","article-title":"Phenytoin-induced chorea: Drug interaction or genetic predisposition?","volume":"39","author":"Gonz\u00e1lez Ot\u00e1rula","year":"2016","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0280","doi-asserted-by":"crossref","first-page":"E51","DOI":"10.1176\/appi.neuropsych.12120396","article-title":"Orolingual dyskinesia and involuntary neck movements caused by phenytoin intoxication","volume":"25","author":"Gunduz","year":"2013","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.yebeh.2022.108693_b0285","first-page":"107","article-title":"Persistent cerebellar ataxia with cerebellar cognitive affective syndrome due to acute phenytoin intoxication: A case report","volume":"18","author":"Gupta","year":"2013","journal-title":"Neurol Asia"},{"key":"10.1016\/j.yebeh.2022.108693_b0290","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/0028-3886.76862","article-title":"Phenytoin toxicity presenting as acute meningo-encephalitis in children","volume":"59","author":"Gupta","year":"2011","journal-title":"Neurol India"},{"key":"10.1016\/j.yebeh.2022.108693_b0295","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1136\/pgmj.66.782.1089","article-title":"Phenytoin-induced choreoathetosis","volume":"66","author":"Haider","year":"1990","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b0300","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/0002-9394(82)90207-0","article-title":"Unidirectional gaze paretic nystagmus induced by phenytoin intoxication","volume":"94","author":"Herishanu","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.yebeh.2022.108693_b0305","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1177\/000992288502400902","article-title":"Phenytoin-induced movement disorder associated with intravenous administration for status epilepticus","volume":"24","author":"Howrie","year":"1985","journal-title":"Clin Pediatr"},{"key":"10.1016\/j.yebeh.2022.108693_b0310","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1191\/0269216306pm1150cr","article-title":"A case of phenytoin toxicity in a patient with advanced lung cancer","volume":"20","author":"Jenkins","year":"2006","journal-title":"Palliative Med"},{"key":"10.1016\/j.yebeh.2022.108693_b0315","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5530\/jyp.2019.11.24","article-title":"Ataxia, manifestation of phenytoin toxicity: A case report","volume":"11","author":"Juhi","year":"2019","journal-title":"J Young Pharm"},{"key":"10.1016\/j.yebeh.2022.108693_b0320","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.yebeh.2016.03.010","article-title":"Orofacial dyskinesias by phenytoin in an elderly female: The dangers of poor therapeutic monitoring","volume":"59","author":"Kaur","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b0325","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/088307389601100617","article-title":"Phenytoin-related chorea in children with deep hemispheric vascular malformations","volume":"11","author":"Koukkari","year":"1996","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0330","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1542\/peds.72.6.831","article-title":"Phenytoin-induced choreoathetosis in infancy: Case reports and a review","volume":"72","author":"Krishnamoorthy","year":"1983","journal-title":"Pediatrics"},{"key":"10.1016\/j.yebeh.2022.108693_b0335","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/00002826-198810000-00008","article-title":"Long-lasting movement disorder induced by intravenous phenytoin administration for status epilepticus. A case report","volume":"11","author":"Kurata","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0340","first-page":"274","article-title":"Involuntary movements induced by anticonvulsants drugs","volume":"49","author":"Lazaro","year":"1982","journal-title":"Mt Sinai J Med"},{"key":"10.1016\/j.yebeh.2022.108693_b0345","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/mds.22004","article-title":"Phenytoin intoxication and upper facial dyskinesia: An unusual presentation","volume":"23","author":"Lee","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b0350","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0b013e3182735eac","article-title":"Teaching video NeuroImages: Phenytoin-induced orofacial dyskinesias","volume":"79","author":"Lucey","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b0355","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1528-1157.1977.tb04984.x","article-title":"Phenytoin induced hyperkinesia","volume":"18","author":"Luhdorf","year":"1977","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b0360","first-page":"598","article-title":"Phenytoin intoxication with activated seizure and dyskinesia","volume":"35","author":"Maiti","year":"1987","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.yebeh.2022.108693_b0365","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1159\/000115065","article-title":"Transient hyperkinesia after a single intravenous perfusion of diphenylhydantoin. Report of a case associated with nontoxic plasma levels of diphenylhydantoin","volume":"18","author":"Mauguiere","year":"1979","journal-title":"Eur Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0370","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/bmj.2.5912.204","article-title":"Choreo-athetosis and encephalopathy induced by phenytoin","volume":"2","author":"McLellan","year":"1974","journal-title":"Br Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b0375","doi-asserted-by":"crossref","first-page":"272","DOI":"10.5530\/jyp.2015.3.20","article-title":"Phenytoin toxicity: A case report","volume":"7","author":"Menon","year":"2015","journal-title":"J Young Pharm"},{"key":"10.1016\/j.yebeh.2022.108693_b0380","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1590\/S0004-282X1999000300002","article-title":"Dyskinesia induced by phenytoin","volume":"57","author":"Montenegro","year":"1999","journal-title":"Arq Neuro-Psiquiatr"},{"key":"10.1016\/j.yebeh.2022.108693_b0385","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/000992289403301012","article-title":"Phenytoin-induced movement disorder: Unilateral presentation in a child and response to diphenhydramine","volume":"33","author":"Moss","year":"1994","journal-title":"Clin Pediatr"},{"key":"10.1016\/j.yebeh.2022.108693_b0390","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/875512259701300305","article-title":"Multiple episodes of phenytoin toxicity in an elderly patient","volume":"13","author":"Namjoshi","year":"1997","journal-title":"J Pharm Technol"},{"key":"10.1016\/j.yebeh.2022.108693_b0395","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF01247146","article-title":"Clinical and experimental studies of phenytoin-induced hyperkinesias","volume":"45","author":"Nausieda","year":"1979","journal-title":"J Neural Transm Gen Sect"},{"key":"10.1016\/j.yebeh.2022.108693_b0400","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2174\/1574886313666181031161215","article-title":"Phenytoin induced chorea: A rare adverse effect of the drug","volume":"14","author":"Patel","year":"2019","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.yebeh.2022.108693_b0405","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.clineuro.2014.10.004","article-title":"Ocular motor abnormalities in a patient with phenytoin toxicity - case report and minireview","volume":"127","author":"Praveen-Kumar","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.yebeh.2022.108693_b0410","first-page":"386","article-title":"Total external ophthalmoplegia induced by phenytoin: A case report and review of literature","volume":"52","author":"Puri","year":"2004","journal-title":"Neurol India"},{"key":"10.1016\/j.yebeh.2022.108693_b0415","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-009246","article-title":"Orofaciolingual dyskinesia due to diphenylhydantoin sodium","author":"Rajasekharan","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.yebeh.2022.108693_b0420","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s12098-020-03392-y","article-title":"Phenytoin induced status dystonicus: A rare manifestation of phenytoin toxicity in a child with autism spectrum disorder","volume":"88","author":"Rajkumar","year":"2021","journal-title":"Indian J Pediatr"},{"key":"10.1016\/j.yebeh.2022.108693_b0425","first-page":"27","article-title":"Permanent ataxia from phenytoin toxicity","volume":"43","author":"Reilly","year":"1990","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.yebeh.2022.108693_b0430","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-008023","article-title":"When less is more: A case of phenytoin toxicity","author":"Robertson","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.yebeh.2022.108693_b0435","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1055\/s-2001-19116","article-title":"Phenytoin-induced choreoathetosis in patients with severe myoclonic epilepsy in infancy","volume":"32","author":"Saito","year":"2001","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.yebeh.2022.108693_b0440","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mds.870110128","article-title":"Phenytoin-induced focal chorea","volume":"11","author":"Shulman","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b0445","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-203000","article-title":"Myristicin and phenytoin toxicity in an infant","author":"Sivathanu","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.yebeh.2022.108693_b0450","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00007691-198802000-00022","article-title":"Choreoathetosis induced by ordinary phenytoin levels, explained by high free fraction? - A case report","volume":"10","author":"Tomson","year":"1988","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.yebeh.2022.108693_b0455","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.4103\/0976-3147.145254","article-title":"Opsoclonus - myoclonus syndrome induced by phenytoin intoxication","volume":"5","author":"Verma","year":"2014","journal-title":"J Neurosci Rural Pract"},{"key":"10.1016\/j.yebeh.2022.108693_b0460","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/BF00313713","article-title":"Phenytoin-induced orofacial dyskinesia. A case report","volume":"231","author":"Yoshida","year":"1985","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0465","first-page":"75","article-title":"Acute athetosis as a result of phenytoin toxicity in a child","volume":"130","author":"Zinsmeister","year":"1976","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.yebeh.2022.108693_b0470","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/mds.870080104","article-title":"Phenytoin and dyskinesias: A report of two cases and review of the literature","volume":"8","author":"Harrison","year":"1993","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b0475","doi-asserted-by":"crossref","unstructured":"Kumar S, Sarangi SC, Tripathi M, Gupta YK. Evaluation of adverse drug reaction profile of antiepileptic drugs in persons with epilepsy: A cross-sectional study. Epilepsy Behav 2020;105:106947.","DOI":"10.1016\/j.yebeh.2020.106947"},{"key":"10.1016\/j.yebeh.2022.108693_b0480","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.seizure.2018.01.019","article-title":"Phenytoin-related ataxia in patients with epilepsy: Clinical and radiological characteristics","volume":"56","author":"Shanmugarajah","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b0485","doi-asserted-by":"crossref","unstructured":"Anderson M, Egunsola O, Cherrill J, Millward C, Fakis A, Choonara I. A prospective study of adverse drug reactions to antiepileptic drugs in children. BMJ Open 2015;5:e008298.","DOI":"10.1136\/bmjopen-2015-008298"},{"key":"10.1016\/j.yebeh.2022.108693_b0490","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s11011-014-9514-7","article-title":"Asterixis: A study of 103 patients","volume":"29","author":"Pal","year":"2014","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.yebeh.2022.108693_b0495","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WNF.0b013e31829a498d","article-title":"Adverse effects of antiepileptic drugs in north indian pediatric outpatients","volume":"36","author":"Bansal","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0500","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3747\/co.v18i6.839","article-title":"Phenytoin toxicity in a patient receiving 5-fluorouracil-based chemotherapy for metastatic colorectal cancer","volume":"18","author":"Kuruvilla","year":"2011","journal-title":"Curr Oncol"},{"key":"10.1016\/j.yebeh.2022.108693_b0505","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clineuro.2009.12.014","article-title":"Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult chinese patients","volume":"112","author":"Zeng","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.yebeh.2022.108693_b0510","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5001\/omj.2010.5","article-title":"Correlation between serum level of antiepileptic drugs and their side effects","volume":"25","author":"Hussein","year":"2010","journal-title":"Oman Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b0515","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/jnnp.2006.100222","article-title":"Movement disorders in patients taking anticonvulsants","volume":"78","author":"Zadikoff","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b0520","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1528-1157.1992.tb02331.x","article-title":"Alterations of ballistic movements in epileptic patients with phenytoin intoxication","volume":"33","author":"Benvenuti","year":"1992","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b0525","doi-asserted-by":"crossref","unstructured":"Cohen AF, Ashby L, Crowley D. Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol 1985;20:619-29.","DOI":"10.1111\/j.1365-2125.1985.tb05120.x"},{"key":"10.1016\/j.yebeh.2022.108693_b0530","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000119516","article-title":"Phenytoin overdosage and cerebellar atrophy in epileptic patients: Clinical and MRI findings","volume":"34","author":"Luef","year":"1994","journal-title":"Eur Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0535","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0896-6974(98)00021-8","article-title":"A case of cerebellar atrophy after phenytoin intoxication: Neurologic, neuroradiologic, and neuropsychological findings","volume":"11","author":"Pulliainen","year":"1998","journal-title":"J Epilepsy"},{"key":"10.1016\/j.yebeh.2022.108693_b0540","doi-asserted-by":"crossref","unstructured":"Panachiyil GM, Babu T, Sebastian J, Ravi MD. A case report of fosphenytoin induced orofacial dyskinesia in an 11-month-old baby with post-encephalitic sequelae. J Clin Diagn Res 2019;13:SD07-8.","DOI":"10.7860\/JCDR\/2019\/41483.12869"},{"key":"10.1016\/j.yebeh.2022.108693_b0545","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jns.2013.04.013","article-title":"Fosphenytoin induced transient pendular nystagmus","volume":"330","author":"Shaikh","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2022.108693_b0550","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1212\/WNL.0000000000002595","article-title":"Fosphenytoin-induced dyskinesias in an infant with sturge-weber syndrome","volume":"86","author":"Thodeson","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b0555","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0920-1211(97)00054-5","article-title":"Intramuscular fosphenytoin (cerebyx\u00ae) in patients requiring a loading dose of phenytoin","volume":"28","author":"Ramsay","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b0560","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/00002826-199310000-00009","article-title":"Parkinsonian syndrome in childhood after sodium valproate administration","volume":"16","author":"Alvarez-Gomez","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0565","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000446643","article-title":"Reversible valproate induced Pisa syndrome and parkinsonism in a neuro-oncology patient with depression and epilepsy","volume":"8","author":"Botturi","year":"2016","journal-title":"Case Rep Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0570","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ebcr.2017.04.002","article-title":"Non-hyperammonaemic valproate encephalopathy after 20 years of treatment","volume":"8","author":"Caruana Galizia","year":"2017","journal-title":"Epilepsy Behav Case Report"},{"key":"10.1016\/j.yebeh.2022.108693_b0575","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/392091","article-title":"Valproic acid-induced myoclonus in a demented patient: A case report","volume":"2009","author":"Gardner","year":"2009","journal-title":"Case Rep Med"},{"key":"10.1016\/j.yebeh.2022.108693_b0580","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/mdc3.12069","article-title":"Valproate-induced generalized choreoathetosis","volume":"1","author":"Giordano","year":"2014","journal-title":"Mov Disord Clin Pract"},{"key":"10.1016\/j.yebeh.2022.108693_b0585","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1053\/seiz.2001.0576","article-title":"Reversible valproate-induced choreiform movements","volume":"11","author":"Gunal","year":"2002","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b0590","first-page":"213","article-title":"Reversible valproic acid-induced parkinsonism and cognitive impairment in an elderly patient with bipolar disorder I","volume":"27","author":"Hassamal","year":"2016","journal-title":"Turk Psikiyatri Derg Fall"},{"key":"10.1016\/j.yebeh.2022.108693_b0595","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/136515001317021716","article-title":"Acute akathisia and sodium valproate","volume":"5","author":"Haut","year":"2001","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1016\/j.yebeh.2022.108693_b0600","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4088\/JCP.v63n0114a","article-title":"Valproate-induced parkinsonism in a demented elderly patient [1]","volume":"63","author":"Iijima","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b0605","first-page":"235","article-title":"Valproate-induced reversible 'parkinsonism plus' syndrome","volume":"11","author":"Khwaja","year":"2010","journal-title":"J Indian Acad Clin Med"},{"key":"10.1016\/j.yebeh.2022.108693_b0610","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1001\/archneur.1994.00540190086020","article-title":"Choreiform movements associated with the use of valproate","volume":"51","author":"Lancman","year":"1994","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0615","first-page":"38","article-title":"Valproate-induced parkinsonism in epilepsy patient - A case report","volume":"35","author":"Maximov","year":"2008","journal-title":"Acta Med Bulg"},{"key":"10.1016\/j.yebeh.2022.108693_b0620","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.pediatrneurol.2006.06.009","article-title":"Valproate-induced chorea and encephalopathy in atypical nonketotic hyperglycinemia","volume":"35","author":"Morrison","year":"2006","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0625","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/j.0013-9580.2004.69603.x","article-title":"Spasmodic dysphonia induced by valproic acid","volume":"45","author":"Oh","year":"2004","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b0630","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s004150050288","article-title":"Reversible parkinsonism induced by prolonged treatment with valproate","volume":"245","author":"Onofrj","year":"1998","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0635","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/mds.22328","article-title":"Pisa syndrome and parkinson secondary to valproic acid in huntington's disease","volume":"23","author":"Salazar","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b0640","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1528-1157.1994.tb02449.x","article-title":"Reversible valproate-induced extrapyramidal disorders","volume":"35","author":"Sasso","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b0645","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.pnpbp.2008.03.022","article-title":"Valproate-induced parkinsonism, glial cells and alexander's disease","volume":"32","author":"Sechi","year":"2008","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b0650","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.parkreldis.2013.03.016","article-title":"Valproic acid-induced parkinsonism: Levodopa responsiveness with dyskinesia","volume":"19","author":"Silver","year":"2013","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b0655","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1002\/mds.23119","article-title":"Valproate-induced reversible hemichorea","volume":"25","author":"Srinivasan","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b0660","first-page":"220","article-title":"Acute chorea caused by valproate in an elderly","volume":"111","author":"van de Velde","year":"2011","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.yebeh.2022.108693_b0665","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1176\/appi.ajp.163.2.325-a","article-title":"Pisa syndrome in a patient in a wheelchair taking valproic acid [2]","volume":"163","author":"Yohanan","year":"2006","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b0670","first-page":"8","article-title":"Disabling resting tremors induced by the short-term infusion of valproate: A reversible phenomenon","author":"Gupta","year":"2018","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"10.1016\/j.yebeh.2022.108693_b0675","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1532-5415.2007.01117.x","article-title":"Reversible cognitive and neurological symptoms during valproic acid therapy [6]","volume":"55","author":"Hommet","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.yebeh.2022.108693_b0680","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.pediatrneurol.2013.03.004","article-title":"Asymmetric drug-induced tremor: Rare feature of a common event","volume":"48","author":"Kakisaka","year":"2013","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0685","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40199-020-00333-0","article-title":"Valproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction","volume":"28","author":"Miyauchi","year":"2020","journal-title":"DARU"},{"key":"10.1016\/j.yebeh.2022.108693_b0690","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2174\/1574886311308010010","article-title":"Sodium valproate induced tremor in a patient with epilepsy and Down's syndrome","volume":"8","author":"Siniscalchi","year":"2013","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.yebeh.2022.108693_b0695","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0013-4694(94)00268-P","article-title":"Negative myoclonus during valproate-related stupor. Neurophysiological evidence of a cortical non-epileptic origin","volume":"94","author":"Aguglia","year":"1995","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"10.1016\/j.yebeh.2022.108693_b0700","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/mds.23828","article-title":"Drug-induced parkinsonism: A review of 17 years' experience in a regional pharmacovigilance center in france","volume":"26","author":"Bondon-Guitton","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b0705","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1212\/01.WNL.0000121228.32913.00","article-title":"Reversible parkinsonism with normal beta-CIT-SPECT in patients exposed to sodium valproate","volume":"62","author":"Easterford","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b0710","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/mds.21188","article-title":"Valproate-induced parkinsonism in epilepsy patients","volume":"22","author":"Jamora","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b0715","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-2006-931471","article-title":"Parkinsonism and\/or cognitive impairment with valproic acid therapy: A report of ten cases","volume":"39","author":"Masmoudi","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b0720","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1353-8020(99)00013-9","article-title":"Prospective evaluation of parkinsonism and tremor in patients treated with valproate","volume":"5","author":"Nouzeilles","year":"1999","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b0725","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0028-1128115","article-title":"Translation of randomised controlled trial findings into clinical practice: Comparison of olanzapine and valproate in the EMBLEM study","volume":"42","author":"Novick","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b0730","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1046\/j.1526-4610.2002.02127.x","article-title":"Intravenous valproate sodium in the treatment of daily headache","volume":"42","author":"Schwartz","year":"2002","journal-title":"Headache"},{"key":"10.1016\/j.yebeh.2022.108693_b0735","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1017\/S1092852900015315","article-title":"An open-label trial of divalproex extended-release in the treatment of borderline personality disorder","volume":"12","author":"Simeon","year":"2007","journal-title":"CNS Spectr"},{"key":"10.1016\/j.yebeh.2022.108693_b0740","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5530\/jyp.2019.11.40","article-title":"Intensive monitoring of adverse drug reactions to antiepileptic drugs in neurology department of a secondary care hospital in U.A.E","volume":"11","author":"Alkhalil","year":"2019","journal-title":"J Young Pharm"},{"key":"10.1016\/j.yebeh.2022.108693_b0745","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/ane.12953","article-title":"Distinguishing features between valproate-induced tremor and essential tremor","volume":"138","author":"Alonso-Juarez","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108693_b0750","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.parkreldis.2017.09.011","article-title":"The clinical features and functional impact of valproate-induced tremor","volume":"44","author":"Alonso-Juarez","year":"2017","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b0755","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s13760-019-01239-8","article-title":"Valproate-induced rest tremor and parkinsonism","volume":"121","author":"Baizabal-Carvallo","year":"2021","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.yebeh.2022.108693_b0760","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3923\/ijp.2010.670.675","article-title":"Assessment of the middle dose of topiramate in comparison with sodium valproate for migraine prophylaxis: A randomized-double-blind study; rouzdarou pharmaceutical (Iran); sobhan (Iran)","volume":"6","author":"Bavrasad","year":"2010","journal-title":"Int J Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0765","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/depr.3050030506","article-title":"Adverse events in 583 valproate-treated patients","volume":"3","author":"Calabrese","year":"1996","journal-title":"Depression"},{"key":"10.1016\/j.yebeh.2022.108693_b0770","first-page":"1402","article-title":"Short-term efficacy and safety of valproate sustained-release formulation in newly diagnosed partial epilepsy (VIPe-study): A multicenter observational open-label study","volume":"28","author":"Deleu","year":"2007","journal-title":"Saudi Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b0775","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.seizure.2018.01.018","article-title":"Safety of antiepileptic drugs in children and young people: A prospective cohort study","volume":"56","author":"Egunsola","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b0780","doi-asserted-by":"crossref","unstructured":"Giri VP, Giri OP, Khan FA, Kumar N, Kumar A, Haque A. Valproic acid versus lamotrigine as first-line monotherapy in newly diagnosed idiopathic generalized tonic -Clonic seizures in adults - A randomized controlled trial. J Clin Diagn Res 2016;10:FC01-4.","DOI":"10.7860\/JCDR\/2016\/16911.8121"},{"key":"10.1016\/j.yebeh.2022.108693_b0785","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1001\/archneurol.2012.2203","article-title":"Substitution monotherapy with levetiracetam vs older antiepileptic drugs: A randomized comparative trial","volume":"69","author":"Hakami","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0790","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/00207454.2016.1181631","article-title":"The relationship between valproate induced tremors and circulating neurotransmitters: A preliminary study","volume":"127","author":"Hamed","year":"2017","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.yebeh.2022.108693_b0795","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.4088\/JCP.08m04895yel","article-title":"Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: A double-blind, placebo-controlled study","volume":"70","author":"Houston","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b0800","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.braindev.2011.08.007","article-title":"Long-term effectiveness of ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy","volume":"34","author":"Hwang","year":"2012","journal-title":"Brain Dev"},{"key":"10.1016\/j.yebeh.2022.108693_b0805","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/1574886314666190311112710","article-title":"Adverse drug reactions of anti-epileptic drugs in children with epilepsy: A cross-sectional study","volume":"14","author":"Kaushik","year":"2019","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.yebeh.2022.108693_b0810","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4088\/JCP.08m04854yel","article-title":"Randomized, double-blind, placebo-controlled study of divalproex extended release loading monotherapy in ambulatory bipolar spectrum disorder patients with moderate-to-severe hypomania or mild mania","volume":"71","author":"McElroy","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b0815","first-page":"177","article-title":"Clinical and surface EMG characteristics of valproate induced tremors","volume":"45","author":"Mehndiratta","year":"2005","journal-title":"Electromyogr Clin Neurophysiol"},{"key":"10.1016\/j.yebeh.2022.108693_b0820","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1111\/ane.12216","article-title":"Low-dose sodium valproate in the treatment of idiopathic generalized epilepsies","volume":"129","author":"Mir\u00f3","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108693_b0825","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0022-510X(82)90128-9","article-title":"Truncal ataxia in chronic anticonvulsant treatment. Association with drug-induced folate deficiency","volume":"55","author":"Munoz-Garcia","year":"1982","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2022.108693_b0830","doi-asserted-by":"crossref","unstructured":"Paparella G, Angelini L, De Biase A, Cannavacciuolo A, Colella D, Di Bonaventura C, et al. Clinical and kinematic features of valproate-induced tremor and differences with essential tremor. Cerebellum 2020;20(3):374-383.","DOI":"10.1007\/s12311-020-01216-5"},{"key":"10.1016\/j.yebeh.2022.108693_b0835","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jocn.2012.10.020","article-title":"A randomized open-label observational study to compare the efficacy and tolerability between topiramate and valproate in juvenile myoclonic epilepsy","volume":"20","author":"Park","year":"2013","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.yebeh.2022.108693_b0840","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/j.1528-1157.1999.tb00832.x","article-title":"The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: Evidence for a pharmacodynamic interaction","volume":"40","author":"Pisani","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b0845","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/0972-2327.34797","article-title":"An assessment of the clinical equivalence of valproate chrono and extended release divalproex formulations; Ranbaxy (India)","volume":"10","author":"Rajesh","year":"2007","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0850","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.euroneuro.2014.03.010","article-title":"Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial","volume":"24","author":"Sarchielli","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0855","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1177\/0091270009347870","article-title":"Efficacy of sodium valproate and haloperidol in the management of acute mania: A randomized open-label comparative study","volume":"50","author":"Sekhar","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0860","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ajp.2015.11.009","article-title":"Safety and effectiveness of divalproex sodium extended release containing regimen in indian patients with bipolar I disorder in continuation phase: Results of EASED registry","volume":"20","author":"Shah","year":"2016","journal-title":"Asian J Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b0865","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/epi4.12349","article-title":"Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy","volume":"4","author":"Silvennoinen","year":"2019","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.yebeh.2022.108693_b0870","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0896-6974(91)90120-8","article-title":"Conversion to valproate monotherapy in nonretarded adults with primary generalized tonic-clonic seizures","volume":"4","author":"Spitz","year":"1991","journal-title":"J Epilepsy"},{"key":"10.1016\/j.yebeh.2022.108693_b0875","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.seizure.2005.09.011","article-title":"The LAM-SAFE study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults","volume":"14","author":"Steinhoff","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b0880","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.eplepsyres.2007.04.009","article-title":"Sodium valproate versus lamotrigine: A randomised comparison of efficacy, tolerability and effects on circulating androgenic hormones in newly diagnosed epilepsy","volume":"75","author":"Stephen","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b0885","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1111\/j.1600-0404.2011.01568.x","article-title":"Effects of the abrupt switch from solution to modified-release granule formulation of valproate","volume":"125","author":"Verrotti","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108693_b0890","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0404.2011.01488.x","article-title":"Self-reported symptoms in patients on antiepileptic drugs in monotherapy","volume":"124","author":"Wieshmann","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108693_b0895","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.seizure.2019.02.002","article-title":"The clinical characteristics and related factors of tremor in patients with epilepsy","volume":"66","author":"Xiao","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b0900","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.seizure.2013.12.001","article-title":"Efficacy and tolerability of the first antiepileptic drug in children with newly diagnosed idiopathic epilepsy","volume":"23","author":"Yilmaz","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b0905","doi-asserted-by":"crossref","unstructured":"Zeng Q-, Fan T-, Zhu P, He RQ, Bao YX, Zheng RY, et al. Comparative long-term effectiveness of a monotherapy with five antiepileptic drugs for focal epilepsy in adult patients: A prospective cohort study. PLoS One. 2015;10(7):e0131566.","DOI":"10.1371\/journal.pone.0131566"},{"key":"10.1016\/j.yebeh.2022.108693_b0910","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0196-0644(95)70175-3","article-title":"Pediatric carbamazepine intoxication","volume":"25","author":"Stremski","year":"1995","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.yebeh.2022.108693_b0915","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1159\/000342669","article-title":"Levetiracetam versus carbamazepine in patients with late poststroke seizures: A multicenter prospective randomized open-label study (epic project)","volume":"34","author":"Consoli","year":"2012","journal-title":"Cerebrovasc Dis"},{"key":"10.1016\/j.yebeh.2022.108693_b0920","first-page":"144","article-title":"Comparision of efficacy and safety of carbamazepine and eslicarbazepine in adult partial and generalized seizures","volume":"7","author":"Jayasutha","year":"2014","journal-title":"Asian J Pharm Clin Res"},{"key":"10.1016\/j.yebeh.2022.108693_b0925","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.seizure.2017.12.008","article-title":"Unblinded, randomized multicenter trial comparing lamotrigine and valproate combination with controlled-release carbamazepine monotherapy as initial drug regimen in untreated epilepsy","volume":"55","author":"Lee","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2019.106220","article-title":"Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial","volume":"159","author":"Schmitz","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b0935","first-page":"159","article-title":"Assessment of antiepileptic drugs usage in a south indian tertiary care teaching hospital","volume":"18","author":"Sebastian","year":"2013","journal-title":"Neurol Asia"},{"key":"10.1016\/j.yebeh.2022.108693_b0940","first-page":"195","article-title":"A multicenter, placebo-controlled, double-blind study of efficacy of a new form of carbamazepine (CarbatrolR) in refractory epileptic patients","volume":"56","author":"Sobaniec","year":"2004","journal-title":"Pol J Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0945","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1528-1157.1987.tb03680.x","article-title":"Carbamazepine-induced nonepileptic myoclonus in a child with benign epilepsy","volume":"28","author":"Aguglia","year":"1987","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b0950","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ncn3.12338","article-title":"Carbamazepine-induced nystagmus in a 29-year-old patient","volume":"8","author":"Al-Sibahee","year":"2020","journal-title":"Neurol Clin Neurosci"},{"key":"10.1016\/j.yebeh.2022.108693_b0955","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/088307388600100313","article-title":"Oculogyric crisis: A distinct toxic effect of carbamazepine","volume":"1","author":"Arnstein","year":"1986","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0960","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4103\/0253-7613.182879","article-title":"Carbamazepine-induced dystonia in an adolescent","volume":"48","author":"Bansal","year":"2016","journal-title":"Indian J Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b0965","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1001\/archneur.1979.00500440092024","article-title":"Carbamazepine-induced oculogyric crisis","volume":"36","author":"Berchou","year":"1979","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b0970","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/jnnp.45.6.560","article-title":"Carbamazepine-induced choreoathetoid dyskinesias","volume":"45","author":"Bimpong-Buta","year":"1982","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b0975","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/pgmj.58.682.525","article-title":"Dystonia associated with carbamazepine toxicity","volume":"58","author":"Bradbury","year":"1982","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b0980","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0002-9394(14)74231-X","article-title":"Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine","volume":"103","author":"Chrousos","year":"1987","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.yebeh.2022.108693_b0985","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1177\/0009922816636354","article-title":"A 16-year-old girl with altered mental status, abducens nerve palsy, and ataxia","volume":"55","author":"Dover","year":"2016","journal-title":"Clin Pediatr"},{"key":"10.1016\/j.yebeh.2022.108693_b0990","first-page":"165","article-title":"Carbamazepine-induced dystonia, a case report","volume":"14","author":"Fadare","year":"2009","journal-title":"Neurol Asia"},{"key":"10.1016\/j.yebeh.2022.108693_b0995","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1528-1157.1995.tb00477.x","article-title":"Oculogyric crisis induced by carbamazepine","volume":"36","author":"Gorman","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1000","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1684\/j.1950-6945.2000.tb00348.x","article-title":"Carbamazepine-induced combined phonic and motor tic in a boy with Down's syndrome","volume":"2","author":"Holtmann","year":"2000","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b1005","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1212\/WNL.30.12.1333","article-title":"Carbamazepine-induced orofacial dyskinesia","volume":"30","author":"Joyce","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b1010","article-title":"Carbamazepine-induced nonepileptic myoclonus in a child with autism and epilepsy","author":"Klrlk","year":"2021","journal-title":"J Pediatr Epilepsy"},{"key":"10.1016\/j.yebeh.2022.108693_b1015","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00002826-198908000-00007","article-title":"Carbamazepine-induced tics","volume":"12","author":"Kurlan","year":"1989","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1020","first-page":"360","article-title":"Persistent dystonia associated with carbamazepine therapy; a case report","volume":"107","author":"Lee","year":"1994","journal-title":"New Zealand Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b1025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1684\/epd.2012.0504","article-title":"Carbamazepine-induced non-epileptic myoclonus and tic-like movements","volume":"14","author":"Magaudda","year":"2012","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b1030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/WNF.0000000000000125","article-title":"Drug-related eyelid nystagmus: Two cases of a rare clinical phenomenon related to carbamazepine and derivatives","volume":"39","author":"Matarazzo","year":"2016","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1035","first-page":"182","article-title":"Akathisia associated with carbamazepine therapy","volume":"105","author":"Milne","year":"1992","journal-title":"N Z Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b1040","doi-asserted-by":"crossref","first-page":"228.e1","DOI":"10.1016\/j.genhosppsych.2009.03.003","article-title":"Restless legs syndrome with carbamazepine-induced osteomalacia: Causal or casual association","volume":"32","author":"Prakash","year":"2010","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b1045","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/0006-3223(92)90040-7","article-title":"Asterixis induced by carbamazepine therapy","volume":"32","author":"Rittmannsberger","year":"1992","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b1050","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/j.1528-1157.1993.tb02119.x","article-title":"Carbamazepine-induced tics","volume":"34","author":"Robertson","year":"1993","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1055","first-page":"1190","article-title":"Akathisia associated with carbamazepine therapy","volume":"143","author":"Schwarcz","year":"1986","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b1060","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3949\/ccjm.57.4.367","article-title":"Carbamazepine-induced dyskinesia and ophthalmoplegia","volume":"57","author":"Schwartzman","year":"1990","journal-title":"Clevel Clin J Med"},{"key":"10.1016\/j.yebeh.2022.108693_b1065","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/pgmj.70.819.54-a","article-title":"Dystonia - a rare manifestation of carbamazepine toxicity [2]","volume":"70","author":"Soman","year":"1994","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b1070","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S0163-8343(01)00177-3","article-title":"Segmental dystonia as the sole manifestation of carbamazepine toxicity","volume":"24","author":"Stryjer","year":"2002","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b1075","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00041327-200403000-00031","article-title":"Postoperative ophthalmoplegia and ataxia due to carbamazepine toxicity facilitated by diltiazem [2]","volume":"24","author":"Wijdicks","year":"2004","journal-title":"J Neuro-Ophthalmol"},{"key":"10.1016\/j.yebeh.2022.108693_b1080","first-page":"441","article-title":"Nystagmus associated with carbamazepine toxicity","volume":"1","author":"Wirfs","year":"2017","journal-title":"Clin Pract Cases Emerg Med"},{"key":"10.1016\/j.yebeh.2022.108693_b1085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF01666855","article-title":"Asterixis as a side effect of carbamazepine therapy","volume":"69","author":"Rittmannsberger","year":"1991","journal-title":"Klin Wochenschr"},{"key":"10.1016\/j.yebeh.2022.108693_b1090","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/s-0028-1091744","article-title":"Clinical experience with clonazepam (rivotril) in the treatment of epilepsies in infancy and childhood","volume":"4","author":"Martin","year":"1973","journal-title":"Neuropadiatrie"},{"key":"10.1016\/j.yebeh.2022.108693_b1095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/pgmj.63.738.311-a","article-title":"Clonazepam-induced Tourette syndrome in a subject with hyperexplexia","volume":"63","author":"Gillman","year":"1987","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b1100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0006-3223(85)90048-4","article-title":"Parkinsonism induced by high doses of diazepam","volume":"20","author":"Suranyi-Cadotte","year":"1985","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b1105","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/epi.12685","article-title":"Safety and effectiveness of long-term treatment with diazepam auto-injector administered by caregivers in an outpatient setting for the treatment of acute repetitive seizures","volume":"55","author":"Rogin","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00319668","article-title":"Divergence paralysis associated with the ingestion of diazepam","volume":"237","author":"Arai","year":"1990","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1115","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1176\/ajp.135.12.1558","article-title":"Oral-buccal dyskinesia symptoms associated with low-dose benzodiazepine treatment","volume":"135","author":"Kaplan","year":"1978","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b1120","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jpainsymman.2007.03.006","article-title":"Subcutaneous midazolam as a cause of extrapyramidal side effects in a patient with prostate cancer","volume":"34","author":"Brown","year":"2007","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.yebeh.2022.108693_b1125","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4103\/0970-9185.98346","article-title":"Midazolam-induced acute dystonia reversed by diazepam","volume":"28","author":"Komur","year":"2012","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1130","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1600-0447.1991.tb05581.x","article-title":"Nocturnal wandering caused by restless legs and short-acting benzodiazepines","volume":"83","author":"Lauerma","year":"1991","journal-title":"Acta Psychiatr Scand"},{"issue":"8","key":"10.1016\/j.yebeh.2022.108693_b1135","article-title":"Adverse drug reaction: Midazolam-induced extrapyramidal symptoms: A case report","volume":"14","author":"McConn","year":"2020","journal-title":"A A Pract"},{"key":"10.1016\/j.yebeh.2022.108693_b1140","doi-asserted-by":"crossref","DOI":"10.1016\/j.pediatrneurol.2015.02.019","article-title":"Rhythmic myoclonic jerking induced by midazolam in a preterm infant","volume":"52","author":"Ozcan","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1145","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/bmj.300.6724.614","article-title":"Acute dystonia induced by midazolam and abolished by flumazenil","volume":"300","author":"Stolarek","year":"1990","journal-title":"Br Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b1150","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/0952-8180(93)90068-P","article-title":"Midazolam-induced athetoid movements of the lower extremities during epidural anesthesia reversed by physostigmine","volume":"5","author":"Vorsanger","year":"1993","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.yebeh.2022.108693_b1155","first-page":"419","article-title":"Orofacial dyskinesias associated with lorazepam therapy","volume":"5","author":"Sandyk","year":"1986","journal-title":"Clin Pharm"},{"key":"10.1016\/j.yebeh.2022.108693_b1160","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000244123","article-title":"Myoclonus associated with lorazepam therapy in very-low-birth-weight infants; Wyeth","volume":"66","author":"Lee","year":"1994","journal-title":"Biol Neonate"},{"key":"10.1016\/j.yebeh.2022.108693_b1165","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1528-1167.2008.01935.x","article-title":"Clobazam in the treatment of lennox-gastaut syndrome","volume":"50","author":"Conry","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/0883073812461943","article-title":"Clobazam for the treatment of intractable epilepsy in children","volume":"28","author":"Perry","year":"2013","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1175","first-page":"527","article-title":"Dyskinesia and akathisia induced by ethosuximide","volume":"132","author":"Ehyai","year":"1978","journal-title":"Am J Dis Child"},{"key":"10.1016\/j.yebeh.2022.108693_b1180","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1001\/archneur.1975.00490440087017","article-title":"Dyskinesia: An unusual reaction to ethosuximide","volume":"32","author":"Kirschberg","year":"1975","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1185","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1177\/0883073820926634","article-title":"Lacosamide-induced dyskinesia in children with intractable epilepsy","volume":"35","author":"Madani","year":"2020","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1190","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.seizure.2012.05.005","article-title":"Clinical experience with oral lacosamide as adjunctive therapy in adult patients with uncontrolled epilepsy: A multicentre study in epilepsy clinics in the United Kingdom (UK)","volume":"21","author":"Flores","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b1195","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.pediatrneurol.2010.12.003","article-title":"Experience with lacosamide in a series of children with drug-resistant focal epilepsy","volume":"44","author":"Guilhoto","year":"2011","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1200","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial; pharma Schwarz (Germany)","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1205","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.seizure.2019.05.016","article-title":"Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures \u2013 an open-label trial","volume":"71","author":"Ferreira","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b1210","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1528-1167.2012.03543.x","article-title":"Safety and tolerability of adjunctive lacosamide intravenous loading dose in lacosamide-naive patients with partial-onset seizures","volume":"54","author":"Fountain","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1215","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.seizure.2015.04.003","article-title":"Long-term efficacy and safety of lacosamide monotherapy in the treatment of partial-onset seizures: A multicenter evaluation","volume":"29","author":"Gir\u00e1ldez","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b1220","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial","volume":"50","author":"Hal\u00e1sz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1225","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.yebeh.2011.08.032","article-title":"Add-on lacosamide: A retrospective study on the relationship between serum concentration, dosage, and adverse events","volume":"22","author":"Hillenbrand","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b1230","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1528-1167.2012.03407.x","article-title":"Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: Results from a phase III open-label extension trial","volume":"53","author":"Husain","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1235","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jsps.2015.01.006","article-title":"Safety of lacosamide in children with refractory partial epilepsy","volume":"23","author":"Pasha","year":"2015","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.yebeh.2022.108693_b1240","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/ane.12451","article-title":"Long-term adjunctive lacosamide treatment in patients with partial-onset seizures","volume":"133","author":"Rosenow","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108693_b1245","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ejpain.2008.05.016","article-title":"Long-term oral lacosamide in painful diabetic neuropathy: A two-year open-label extension trial","volume":"13","author":"Shaibani","year":"2009","journal-title":"Eur J Pain"},{"key":"10.1016\/j.yebeh.2022.108693_b1250","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jpain.2009.01.322","article-title":"Lacosamide in painful diabetic neuropathy: An 18-week double-blind placebo-controlled trial","volume":"10","author":"Shaibani","year":"2009","journal-title":"J Pain"},{"key":"10.1016\/j.yebeh.2022.108693_b1255","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.yebeh.2011.07.035","article-title":"Adjunctive lacosamide in clinical practice: Sodium blockade with a difference?","volume":"22","author":"Stephen","year":"2011","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b1260","doi-asserted-by":"crossref","unstructured":"Stillman MJ. Efficacy and safety of lacosamide in diabetic neuropathic pain: An 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain. 2009;25:376-385: Comments. Headache 2010;50:335.","DOI":"10.1097\/AJP.0b013e318196d2b6"},{"key":"10.1016\/j.yebeh.2022.108693_b1265","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40261-014-0255-5","article-title":"Early add-on lacosamide in a real-life setting: Results of the REALLY study","volume":"35","author":"Villanueva","year":"2014","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.yebeh.2022.108693_b1270","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.yebeh.2013.07.024","article-title":"Control of seizures in different stages of partial epilepsy: LACO-EXP, a Spanish retrospective study of lacosamide","volume":"29","author":"Villanueva","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b1275","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yebeh.2011.11.026","article-title":"Rational polytherapy with lacosamide in clinical practice: Results of a Spanish cohort analysis RELACOVA","volume":"23","author":"Villanueva","year":"2012","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b1280","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1111\/epi.13502","article-title":"Long-term exposure and safety of lacosamide monotherapy for the treatment of partial-onset (focal) seizures: Results from a multicenter, open-label trial","volume":"57","author":"Vossler","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1285","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/epi.12681","article-title":"Conversion to lacosamide monotherapy in the treatment of focal epilepsy: Results from a historical-controlled, multicenter, double-blind study","volume":"55","author":"Wechsler","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1290","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2016.12.015","article-title":"Lacosamide for uncontrolled primary generalized tonic-clonic seizures: An open-label pilot study with 59-week extension","volume":"130","author":"Wechsler","year":"2017","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b1295","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/AJP.0b013e318196d2b6","article-title":"Efficacy and safety of lacosamide in diabetic neuropathic pain: An 18-week double-blind placebo-controlled trial of fixed-dose regimens","volume":"25","author":"Wymer","year":"2009","journal-title":"Clin J Pain"},{"key":"10.1016\/j.yebeh.2022.108693_b1300","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/0883073812462887","article-title":"Efficacy of lacosamide as adjunctive therapy in children with refractory epilepsy","volume":"29","author":"Yorns","year":"2014","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1305","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.seizure.2015.07.001","article-title":"Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial","volume":"31","author":"Zadeh","year":"2015","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b1310","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.yebeh.2015.11.002","article-title":"Prospective audit with adjunctive perampanel: Preliminary observations in focal epilepsy","volume":"54","author":"Brodie","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b1315","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1177\/0883073817709195","article-title":"Clinical experience with perampanel for refractory pediatric epilepsy in one canadian center","volume":"32","author":"Datta","year":"2017","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1320","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b1325","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.04.017","article-title":"Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian Tertiary Care Epilepsy Centre","volume":"390","author":"Morano","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2022.108693_b1330","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1212\/WNL.0000000000001558","article-title":"Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy","volume":"84","author":"Gidal","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b1335","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3988\/jcn.2020.16.1.53","article-title":"Real-life effectiveness and tolerability of perampanel in pediatric patients aged 4 years or older with epilepsy: A Korean National Multicenter Study","volume":"16","author":"Hwang","year":"2020","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1340","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.yebeh.2019.02.004","article-title":"Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy","volume":"94","author":"Ishikawa","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b1345","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.eplepsyres.2015.09.002","article-title":"Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes","volume":"117","author":"Kwan","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b1350","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.yebeh.2018.06.033","article-title":"Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian Pediatric Neurology Clinics","volume":"85","author":"Lin","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b1355","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.braindev.2020.11.005","article-title":"Clinical experience on the use of perampanel in epilepsy among child neurologists in the Philippines","volume":"43","author":"Macrohon","year":"2021","journal-title":"Brain Dev"},{"key":"10.1016\/j.yebeh.2022.108693_b1360","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.yebeh.2016.06.005","article-title":"Adjunctive perampanel in refractory epilepsy: Experience at tertiary epilepsy care center in tours","volume":"61","author":"Maurousset","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b1365","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eplepsyres.2015.04.011","article-title":"Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel","volume":"114","author":"Montouris","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b1370","first-page":"263","article-title":"Perampanel study 207: Long-term open-label evaluation in patients with epilepsy","volume":"126","author":"Rektor","year":"2012","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108693_b1375","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-0038-1675546","article-title":"Safety and efficacy of perampanel as adjunctive therapy in patients with refractory focal epilepsy over 12 months: Clinical experience in a real-world setting","volume":"5","author":"Rinaldi","year":"2018","journal-title":"Int J Epilepsy"},{"key":"10.1016\/j.yebeh.2022.108693_b1380","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106570","article-title":"Perampanel effectiveness and safety as early add-on treatment for focal-onset seizures: PEREAGAL study","volume":"172","author":"Rodr\u00edguez-Osorio","year":"2021","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b1385","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/epi.14520","article-title":"Perampanel in routine clinical use across Europe: Pooled, multicenter, observational data","volume":"59","author":"Rohracher","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1390","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.seizure.2020.09.026","article-title":"Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs","volume":"83","author":"Santamarina","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b1395","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.eplepsyres.2014.03.015","article-title":"A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria","volume":"108","author":"Steinhoff","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b1400","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eplepsyres.2016.08.001","article-title":"Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study","volume":"126","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b1405","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1528-1157.2000.tb00192.x","article-title":"Myoclonus associated with the use of gabapentin","volume":"41","author":"Asconap\u00e9","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1410","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jocn.2018.09.019","article-title":"Gabapentin or pregabalin induced myoclonus: A case series and literature review","volume":"61","author":"Desai","year":"2019","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.yebeh.2022.108693_b1415","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jns.2017.09.019","article-title":"Negative myoclonus induced by gabapentin and pregabalin: A case series and systematic literature review","volume":"382","author":"Kim","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2022.108693_b1420","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0149-2918(95)80067-0","article-title":"Efficacy and tolerability of gabapentin in clinical practice","volume":"17","author":"Morris","year":"1995","journal-title":"Clin Ther"},{"key":"10.1016\/j.yebeh.2022.108693_b1425","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/jama.280.21.1837","article-title":"Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial","volume":"280","author":"Rowbotham","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.yebeh.2022.108693_b1430","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4088\/JCP.v67n0320","article-title":"A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder","volume":"67","author":"Vieta","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b1435","first-page":"145","article-title":"The efficacy of gabapentin in migraine prophylaxis: An observational open label study","volume":"48","author":"Vukovi\u0107","year":"2009","journal-title":"Acta Clin Croat"},{"key":"10.1016\/j.yebeh.2022.108693_b1440","first-page":"357","article-title":"Gabapentin for the treatment of chronic intractable neuropathic pain: A long-term follow-up study","volume":"17","author":"Wong","year":"2005","journal-title":"Pain Physician"},{"key":"10.1016\/j.yebeh.2022.108693_b1445","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.amjopharm.2009.08.001","article-title":"Chorea associated with gabapentin use in an elderly man","volume":"7","author":"Attupurath","year":"2009","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.yebeh.2022.108693_b1450","first-page":"851","article-title":"Choreoathetotic movements: A possible side effect of gabapentin","volume":"46","author":"Buetefisch","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b1455","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3340\/jkns.2008.43.5.237","article-title":"Myoclonus induced by the use of gabapentin","volume":"43","author":"Cho","year":"2008","journal-title":"J Korean Neurosurg Soc"},{"key":"10.1016\/j.yebeh.2022.108693_b1460","first-page":"910","article-title":"Choreoathetosis as a side effect of gabapentin therapy in severely neurologically impaired patients","volume":"54","author":"Chudnow","year":"1997","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1465","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1002\/mds.21911","article-title":"Gabapentin-induced myoclonus: Case report","volume":"23","author":"Ege","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b1470","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.clineuro.2008.11.015","article-title":"Bilateral ballism induced by gabapentin in idiopatic parkinson's disease","volume":"111","author":"Erol","year":"2009","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.yebeh.2022.108693_b1475","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4103\/0971-4065.83744","article-title":"Treatment of gabapentin-induced myoclonus with continuous renal replacement therapy","volume":"22","author":"Guddati","year":"2012","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.yebeh.2022.108693_b1480","article-title":"Gabapentin-induced facial myoclonus in the setting of acute on chronic kidney disease","volume":"11","author":"Hampton","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.yebeh.2022.108693_b1485","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s00415-005-0970-1","article-title":"Gabapentin-induced severe myoclonus in a patient with impaired renal function [3]","volume":"253","author":"Holtkamp","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1490","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/CM9.0000000000000271","article-title":"Reversible dysphagia due to gabapentin-induced jaw myoclonus","volume":"132","author":"Hui","year":"2019","journal-title":"Chin Med J"},{"key":"10.1016\/j.yebeh.2022.108693_b1495","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00002826-200001000-00010","article-title":"Asterixis induced by gabapentin","volume":"23","author":"Jacob","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1500","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ebcr.2013.12.002","article-title":"Myoclonus in renal failure: Two cases of gabapentin toxicity","volume":"2","author":"Kaufman","year":"2014","journal-title":"Epilepsy Behav Case Report"},{"key":"10.1016\/j.yebeh.2022.108693_b1505","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/00004714-200112000-00018","article-title":"Gabapentin-related [5]","volume":"21","author":"Norton","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1510","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1345\/aph.1E503","article-title":"Dystonia induced by gabapentin","volume":"39","author":"Pina","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.yebeh.2022.108693_b1515","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/mds.21209","article-title":"Dyskinesia induced by gabapentin in idiopathic Parkinson's disease [6]","volume":"22","author":"Raju","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b1520","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1528-1157.1996.tb00537.x","article-title":"Movement disorders associated with the use of gabapentin","volume":"37","author":"Reeves","year":"1996","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1525","doi-asserted-by":"crossref","DOI":"10.1016\/j.jemermed.2013.08.024","article-title":"Acute dystonic reaction caused by gabapentin","volume":"46","author":"Rohman","year":"2014","journal-title":"J Emerg Med"},{"key":"10.1016\/j.yebeh.2022.108693_b1530","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1191\/0269216303Pm772cr","article-title":"Myoclonic jerks associated with gabapentin","volume":"17","author":"Scullin","year":"2003","journal-title":"Palliative Med"},{"key":"10.1016\/j.yebeh.2022.108693_b1535","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0278-5846(03)00166-0","article-title":"Asterixis and toxic encephalopathy induced by gabapentin","volume":"28","author":"Sechi","year":"2004","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b1540","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jfma.2012.06.001","article-title":"Gabapentin-induced myoclonus in an elderly with end-stage renal failure","volume":"113","author":"Shea","year":"2014","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.yebeh.2022.108693_b1545","first-page":"276","article-title":"Chorea in a chronic pain patient using gabapentin","volume":"14","author":"Souzdalnitski","year":"2014","journal-title":"Ochsner J"},{"key":"10.1016\/j.yebeh.2022.108693_b1550","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S1059-1311(97)80029-5","article-title":"Isolated ataxia as an idiosyncratic side-effect under gabapentin","volume":"6","author":"Steinhoff","year":"1997","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b1555","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1590\/S0004-282X2008000100029","article-title":"Chorea due to gabapentin monotherapyin a not encephalopatic patient","volume":"66","author":"Twardowschy","year":"2008","journal-title":"Arq Neuro-Psiquiatr"},{"key":"10.1016\/j.yebeh.2022.108693_b1560","doi-asserted-by":"crossref","first-page":"e768","DOI":"10.1097\/MJT.0000000000000942","article-title":"Myoclonus and altered mental status induced by single dose of gabapentin in a patient with end-stage renal disease: A case report and literature review","volume":"26","author":"Yeddi","year":"2018","journal-title":"Am J Ther"},{"key":"10.1016\/j.yebeh.2022.108693_b1565","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10067-007-0744-5","article-title":"Chorea as a side effect of gabapentin (neurontin\u00ae) in a patient with complex regional pain syndrome type 1","volume":"27","author":"Zesiewicz","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.yebeh.2022.108693_b1570","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1093\/pm\/pnw052","article-title":"Gabapentin superadded to a pre-existent regime containing amytriptyline for chronic sciatica","volume":"17","author":"Robertson","year":"2016","journal-title":"Pain Med"},{"key":"10.1016\/j.yebeh.2022.108693_b1575","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ebcr.2013.12.002","article-title":"Myoclonus in renal failure: Two cases of gabapentin toxicity","volume":"2","author":"Kaufman","year":"2013","journal-title":"Epilepsy Behav Case Rep"},{"key":"10.1016\/j.yebeh.2022.108693_b1580","doi-asserted-by":"crossref","first-page":"e768","DOI":"10.1097\/MJT.0000000000000942","article-title":"Myoclonus and altered mental status induced by single dose of gabapentin in a patient with end-stage renal disease: A case report and literature review","volume":"26","author":"Yeddi","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.yebeh.2022.108693_b1585","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.yebeh.2008.05.003","article-title":"Adjunctive pregabalin therapy in mentally retarded, developmentally delayed patients with epilepsy","volume":"13","author":"Modur","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b1590","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.schres.2017.09.014","article-title":"Pregabalin for anxiety in patients with schizophrenia \u2014 A randomized, double-blind placebo-controlled study","volume":"195","author":"Schjerning","year":"2018","journal-title":"Schizophr Res"},{"key":"10.1016\/j.yebeh.2022.108693_b1595","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1600-0404.2011.01507.x","article-title":"Adjunctive pregabalin for uncontrolled partial-onset seizures: Findings from a prospective audit","volume":"124","author":"Stephen","year":"2011","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108693_b1600","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.seizure.2007.05.011","article-title":"Pregabalin as add-on therapy for refractory partial seizures in every day clinical practice","volume":"16","author":"Carre\u00f1o","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b1605","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1111\/j.1528-1167.2005.00341.x","article-title":"Pregabalin add-on treatment in patients with partial seizures: A novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study","volume":"46","author":"Elger","year":"2005","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1610","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.yebeh.2008.04.021","article-title":"Efficacy and tolerability of pregabalin in patients with difficult-to-treat epilepsy and intellectual disability","volume":"13","author":"Huber","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b1615","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1528-1167.2008.01954.x","article-title":"Pregabalin add-on therapy using a flexible, optimized dose schedule in refractory partial epilepsies: A double-blind, randomized, placebo-controlled, multicenter trial","volume":"50","author":"Lee","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1620","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1200\/JCO.2009.24.5647","article-title":"Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1","volume":"28","author":"Loprinzi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.yebeh.2022.108693_b1625","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5079675","article-title":"Pregabalin for refractory radicular leg pain due to lumbar spinal stenosis: A preliminary prospective study","volume":"2016","author":"Orita","year":"2016","journal-title":"Pain Res Manage"},{"key":"10.1016\/j.yebeh.2022.108693_b1630","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.12669\/pjms.35.6.652","article-title":"Clinical efficacy and tolerability of gabapentinoid with current prescription patterns in patients with neuropathic pain","volume":"35","author":"Shaheen","year":"2019","journal-title":"Pak J Med Sci"},{"key":"10.1016\/j.yebeh.2022.108693_b1635","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.seizure.2011.06.022","article-title":"An open-label, add-on study of pregabalin in patients with partial seizures: A multicenter trial in Greece","volume":"20","author":"Tsounis","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b1640","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1185\/030079906X80404","article-title":"Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: A 13-week, randomized trial","volume":"22","author":"Van Seventer","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.yebeh.2022.108693_b1645","first-page":"100","article-title":"Efficacy of pregabalin in childhood refractory partial seizure","volume":"24","author":"Zamani","year":"2014","journal-title":"Iran J Pediatr"},{"key":"10.1016\/j.yebeh.2022.108693_b1650","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.4103\/0028-3886.304071","article-title":"A case of pregabalin-induced parkinsonism","volume":"68","author":"Ari","year":"2020","journal-title":"Neurol India"},{"key":"10.1016\/j.yebeh.2022.108693_b1655","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jns.2013.12.007","article-title":"Perverted head-shaking and positional downbeat nystagmus in pregabalin intoxication","volume":"337","author":"Choi","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2022.108693_b1660","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4103\/0971-4065.125102","article-title":"Pregabalin-associated myoclonic encephalopathy without evidence of drug accumulation in a patient with acute renal failure","volume":"24","author":"Courtois","year":"2014","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.yebeh.2022.108693_b1665","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1345\/aph.1R699","article-title":"Pregabalin-induced akathisia","volume":"47","author":"Dag","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.yebeh.2022.108693_b1670","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s13760-016-0735-x","article-title":"Could pregabalin cause oculomotor symptoms in lower dose? A case with down beat nystagmus as a side effect","volume":"117","author":"Ekinci","year":"2017","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.yebeh.2022.108693_b1675","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s40199-020-00354-9","article-title":"Pregabalin-associated stuttering and frequent blepharospasm: Case report and review; Shandong Zibo Xinhua pharmaceutical company (China); Pfizer (United States)","volume":"28","author":"Ge","year":"2020","journal-title":"DARU J Pharm Sci"},{"key":"10.1016\/j.yebeh.2022.108693_b1680","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/mds.22286","article-title":"Pregabalin- and gabapentin-associated myoclonus in a patient with chronic renal failure","volume":"24","author":"Healy","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b1685","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/01.phm.0000176355.97155.f5","article-title":"Pregabalin associated asterixis","volume":"84","author":"Heckmann","year":"2005","journal-title":"Am J Phys Med Rehabil"},{"key":"10.1016\/j.yebeh.2022.108693_b1690","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.yebeh.2008.04.006","article-title":"Pregabalin-induced cortical negative myoclonus in a patient with neuropathic pain","volume":"13","author":"Hellwig","year":"2008","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b1695","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-201282","article-title":"Delayed onset of rotatory self-motion perception, dysdiadochokinesia and disturbed eye pursuit caused by low-dose pregabalin","author":"Hounnou","year":"2014","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.yebeh.2022.108693_b1700","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.therap.2016.09.001","article-title":"Pregabalin-induced parkinsonism: A case report","volume":"72","author":"Masmoudi","year":"2017","journal-title":"Therapie"},{"key":"10.1016\/j.yebeh.2022.108693_b1705","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.parkreldis.2015.04.026","article-title":"Speech myoclonus due to probable pregabalin adverse drug-reaction","volume":"21","author":"Olszewska","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b1710","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/24750573.2017.1422959","article-title":"Nasal pregabalin overdose and myclonus: A new way of misuse","volume":"29","author":"Ozturk","year":"2019","journal-title":"Psychiatry Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1715","doi-asserted-by":"crossref","first-page":"240","DOI":"10.12701\/yujm.2018.35.2.240","article-title":"Negative myoclonus associated with pregabalin","volume":"35","author":"Park","year":"2018","journal-title":"Yeungnam Univ J Med"},{"key":"10.1016\/j.yebeh.2022.108693_b1720","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/WNF.0b013e3181a9eb1b","article-title":"Pregabalin-induced parkinsonism: A case report","volume":"32","author":"Perez Lloret","year":"2009","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1725","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/jppr.1363","article-title":"Pregabalin-induced parkinsonism 72 hours after iodinated contrast administration","volume":"48","author":"Prado-Mel","year":"2018","journal-title":"J Pharm Pract Res"},{"key":"10.1016\/j.yebeh.2022.108693_b1730","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-007559","article-title":"Disturbance of consciousness and involuntary movements caused by pregabalin","author":"Shimizu","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.yebeh.2022.108693_b1735","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12519-017-0045-2","article-title":"Oxcarbazepine oral suspension in pediatric patients with partial seizures and\/or generalized tonic-clonic seizures: A multi-center, single arm, observational study in China","volume":"13","author":"Wang","year":"2017","journal-title":"World J Pediatr"},{"key":"10.1016\/j.yebeh.2022.108693_b1740","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/ane.12467","article-title":"Long-term efficacy and safety of adjunctive extended-release oxcarbazepine (Oxtellar XR\u00ae) in adults with partial-onset seizures; supernus (United States)","volume":"133","author":"Chung","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108693_b1745","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.seizure.2012.07.007","article-title":"A multicenter trial of oxcarbazepine oral suspension monotherapy in children newly diagnosed with partial seizures: A clinical and cognitive evaluation","volume":"21","author":"Eun","year":"2012","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b1750","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1017\/S1461145708008596","article-title":"A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder","volume":"11","author":"Vieta","year":"2008","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1755","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1007\/s10072-013-1315-y","article-title":"Oxcarbazepine-induced jerky see-saw nystagmus","volume":"34","author":"Adamec","year":"2013","journal-title":"Neurol Sci"},{"key":"10.1016\/j.yebeh.2022.108693_b1760","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1212\/WNL.52.9.1918","article-title":"Elimination of oxcarbazepine-induced oculogyric crisis following vagus nerve stimulation","volume":"52","author":"Gatzonis","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b1765","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/1817-1745.66664","article-title":"Oxcarbazepine-induced tardive dyskinesia: A rare adverse reaction","volume":"5","author":"Herg\u00fcner","year":"2010","journal-title":"J Pediatr Neurosci"},{"key":"10.1016\/j.yebeh.2022.108693_b1770","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.parkreldis.2009.03.007","article-title":"Reversible parkinsonism with oxcarbazepine use","volume":"15","author":"Okuyucu","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b1775","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ebcr.2017.04.005","article-title":"Vertical gaze palsy due to medication error","volume":"8","author":"Rao","year":"2017","journal-title":"Epilepsy Behav Case Report"},{"key":"10.1016\/j.yebeh.2022.108693_b1780","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/ejp.1192","article-title":"Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia","volume":"22","author":"Sanchez-Larsen","year":"2018","journal-title":"Eur J Pain"},{"key":"10.1016\/j.yebeh.2022.108693_b1785","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/cns.12765","article-title":"Pooled efficacy and safety of eslicarbazepine acetate as add-on treatment in patients with focal-onset seizures: Data from four double-blind placebo-controlled pivotal phase III clinical studies","volume":"23","author":"Elger","year":"2017","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.yebeh.2022.108693_b1790","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s40264-017-0576-4","article-title":"Safety profile of eslicarbazepine acetate as add-on therapy in adults with refractory focal-onset seizures: From clinical studies to 6 years of post-marketing experience; bial Portela and C (Portugal); Sunovion (United States)","volume":"40","author":"Gama","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.yebeh.2022.108693_b1795","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.seizure.2017.04.003","article-title":"Efficacy and safety of eslicarbazepine-acetate in elderly patients with focal epilepsy: Case series","volume":"48","author":"G\u00f3mez-Ib\u00e1\u00f1ez","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b1800","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.eplepsyres.2012.07.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy: Results of a 1-year open-label extension study","volume":"103","author":"Hufnagel","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b1805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2017.10.021","article-title":"Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate: An integrated analysis of three randomized placebo-controlled trials","volume":"139","author":"Krauss","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b1810","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.seizure.2019.12.022","article-title":"Safety, tolerability and effectiveness of transition to eslicarbazepine acetate from carbamazepine or oxcarbazepine in clinical practice","volume":"75","author":"Rocamora","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b1815","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/ane.13323","article-title":"Eslicarbazepine acetate in post-stroke epilepsy: Clinical practice evidence from euro-esli","volume":"142","author":"Sales","year":"2020","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108693_b1820","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/epi.12894","article-title":"Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial","volume":"56","author":"Sperling","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1825","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.eplepsyres.2014.04.014","article-title":"Long-term safety and efficacy of eslicarbazepine acetate in patients with focal seizures: Results of the 1-year ESLIBASE retrospective study","volume":"108","author":"Villanueva","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b1830","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/WNF.0000000000000020","article-title":"Generalized myoclonus and spasticity induced by lamotrigine toxicity: A case report and literature review","volume":"37","author":"Algahtani","year":"2014","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1835","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2004.11.004","article-title":"Downbeat nystagmus as a result of lamotrigine toxicity","volume":"63","author":"Alkawi","year":"2005","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b1840","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.pnpbp.2007.04.015","article-title":"Co-occurence of blepharospasm, tourettism and obsessive-compulsive symptoms during lamotrigine treatment","volume":"31","author":"Alkin","year":"2007","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b1845","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/1574886311207040269","article-title":"Lamotrigine induced whole body tics: A case report and literature review","volume":"11","author":"Centorino","year":"2016","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.yebeh.2022.108693_b1850","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1212\/01.wnl.0000174517.21383.36","article-title":"Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies","volume":"65","author":"Crespel","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b1855","first-page":"39","article-title":"Dopa-responsive dystonia subsequent to lamotrigine administration: Case reports","volume":"12","author":"Ebrahimi","year":"2013","journal-title":"Iran J Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2022.108693_b1860","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/JCP.0b013e318167465f","article-title":"Myoclonus provoked by lamotrigine in a bipolar patient","volume":"28","author":"Fern\u00e1ndez Corcuera","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1865","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00002826-200003000-00005","article-title":"Disabling erratic myoclonus during lamotrigine therapy with high serum level - report of two cases","volume":"23","author":"Janszky","year":"2000","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1870","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.106013","article-title":"Gaze-evoked nystagmus associated with valproic acid-induced lamotrigine toxicity","volume":"196","author":"Jung","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.yebeh.2022.108693_b1875","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3988\/jcn.2007.3.2.93","article-title":"A case of lamotrigine-induced excessive involuntary eye blinking","volume":"3","author":"Kim","year":"2007","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1880","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.52.6.1191","article-title":"Lamotrigine-induced tourettism","volume":"52","author":"Lombroso","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b1885","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1089\/cap.2013.0057","article-title":"Lamotrigine-induced facial tic in a pediatric bipolar disorder patient","volume":"23","author":"Lu","year":"2013","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1890","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/18715249113136660060","article-title":"Dystonia associated with lamotrigine therapy: A case report and review of the literature","volume":"9","author":"Marrero-Gonzalez","year":"2014","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.yebeh.2022.108693_b1895","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1590\/S1676-26492007000400008","article-title":"Late side-effects of valproate and lamotrigine","volume":"13","author":"Moreira","year":"2007","journal-title":"J Epilepsy Clin Neurophysiol"},{"key":"10.1016\/j.yebeh.2022.108693_b1900","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3988\/jcn.2006.2.4.283","article-title":"Downbeat, positional, and perverted head-shaking nystagmus associated with lamotrigine toxicity","volume":"2","author":"Oh","year":"2006","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1905","article-title":"Lamotrigine induced dyskinesia in parkinson's disease; Bristol Myers Squibb (Germany); Glaxo SmithKline (Germany); Lundbeck (Germany); Orion (Germany)","volume":"17","author":"Sabolek","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1910","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1002\/mds.21125","article-title":"Parkinsonism due to lamotrigine [9]","volume":"21","author":"Santens","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b1915","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1528-1157.2000.tb00254.x","article-title":"Lamotrigine-induced tic disorder: Report of five pediatric cases","volume":"41","author":"Sotero De Menezes","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1920","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2016.12.022","article-title":"De novo multifocal myoclonus induced by lamotrigine in a temporal lobe epilepsy case","volume":"373","author":"Tombini","year":"2017","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2022.108693_b1925","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1111\/j.1528-1167.2010.02967.x","article-title":"Oculogyric crises secondary to lamotrigine overdosage","volume":"52","author":"Veerapandiyan","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b1930","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1592\/phco.19.10.877.31554","article-title":"Lamotrigine-induced blepharospasm","volume":"19","author":"Verma","year":"1999","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.yebeh.2022.108693_b1935","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/mds.21585","article-title":"Lamotrigine-induced bilateral ballism [4]","volume":"22","author":"Yetimalar","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b1940","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/08830738060210041301","article-title":"Chorea induced by lamotrigine [1]","volume":"21","author":"Zesiewicz","year":"2006","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1945","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/mds.23120","article-title":"Facial tic associated with lamotrigine in adults","volume":"25","author":"Musiek","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b1950","doi-asserted-by":"crossref","first-page":"18","DOI":"10.14802\/jmd.10005","article-title":"Action tremor associated with lamotrigine monotherapy","volume":"3","author":"Yang","year":"2010","journal-title":"J Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b1955","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1620\/tjem.248.273","article-title":"Lamotrigine induces tremor among epilepsy patients probably via cerebellar pathways","volume":"248","author":"Kov\u00e1cs","year":"2019","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.yebeh.2022.108693_b1960","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/jnnp-2011-301999","article-title":"The LaLiMo trial: Lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy - an open-label, prospective, randomised controlled multicenter study","volume":"83","author":"Rosenow","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b1965","first-page":"33","article-title":"Efficacy and safety of lamotrigine in lennox-gastaut syndrome","volume":"3","author":"Fallah","year":"2009","journal-title":"Iran J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b1970","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/YIC.0b013e328014823d","article-title":"Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: A randomized, open-label study","volume":"22","author":"Schindler","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1975","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0920-1211(90)90019-R","article-title":"The efficacy and long-term tolerability of lamotrigine in the treatment of severe epilepsy","volume":"7","author":"Sander","year":"1990","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b1980","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11060-017-2660-0","article-title":"Efficacy and safety of levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma","volume":"136","author":"Cardona","year":"2018","journal-title":"J Neuro-Oncol"},{"key":"10.1016\/j.yebeh.2022.108693_b1985","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1177\/0333102419851814","article-title":"Levetiracetam for prophylactic treatment of pediatric migraine: A randomized double-blind placebo-controlled trial","volume":"39","author":"Montazerlotfelahi","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.yebeh.2022.108693_b1990","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/01.WNF.0000240946.51994.DF","article-title":"Levetiracetam-induced parkinsonism in a huntington disease patient","volume":"29","author":"Gatto","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b1995","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-019-1519-8","article-title":"A case of dyskinesia after levetiracetam administration","volume":"19","author":"Yim","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2000","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/01.wnf.0000169732.00690.32","article-title":"Levetiracetam-induced parkinsonism in a Huntington disease patient; UCB (United States)","volume":"28","author":"Zesiewicz","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b2005","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.eplepsyres.2018.06.002","article-title":"Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program","volume":"145","author":"Brodie","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b2010","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106657","article-title":"Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy","volume":"102","author":"Fonseca","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b2015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.seizure.2017.03.010","article-title":"Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy\u2014A monocenter survey","volume":"48","author":"Steinhoff","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b2020","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/epi.13768","article-title":"Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany","volume":"58","author":"Steinig","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b2025","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","article-title":"An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam","volume":"52","author":"Yates","year":"2015","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b2030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.WNF.0000220825.65393.93","article-title":"Reversible tremor, myoclonus, and fasciculations associated with topiramate use for migraine","volume":"29","author":"Alonso-Navarro","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b2035","first-page":"22","article-title":"Topiramate-induced facial myoclonus","volume":"14","author":"Ginsberg","year":"2007","journal-title":"Prim psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b2040","first-page":"7901085","article-title":"Topiramate-induced persistent eyelid myokymia","volume":"2016","author":"Khalkhali","year":"2016","journal-title":"Case Rep Psychiatry"},{"key":"10.1016\/j.yebeh.2022.108693_b2045","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1111\/j.1528-1167.2007.01165_3.x","article-title":"Reversible facial myoclonus with topiramate therapy for epilepsy [2]","volume":"48","author":"Kutluay","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b2050","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.2146\/ajhp090185","article-title":"Topiramate-induced myoclonus and psychosis during migraine prophylaxis","volume":"67","author":"Miller","year":"2010","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.yebeh.2022.108693_b2055","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1007\/s00415-007-0243-z","article-title":"Topiramate-induced restless legs syndrome: A report of two cases [3]","volume":"254","author":"Romigi","year":"2007","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ebcr.2014.04.002","article-title":"Topiramate-induced periodic limb movement disorder in a patient affected by focal epilepsy","volume":"2","author":"Romigi","year":"2014","journal-title":"Epilepsy Behav Case Report"},{"key":"10.1016\/j.yebeh.2022.108693_b2065","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1007\/s00415-009-0073-5","article-title":"Restless legs syndrome induced by topiramate: Two more cases","volume":"256","author":"Bermejo","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/15563650500357552","article-title":"Pediatric case report of topiramate toxicity","volume":"44","author":"Lin","year":"2006","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.yebeh.2022.108693_b2075","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/ane.12395","article-title":"Eyelid myokymia in patients with migraine taking topiramate","volume":"132","author":"Medrano-Mart\u00ednez","year":"2015","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108693_b2080","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.12134","article-title":"Intravenous topiramate: Comparison of pharmacokinetics and safety with the oral formulation in healthy volunteers; janssen (United States)","volume":"54","author":"Clark","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b2085","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2165\/11593850-000000000-00000","article-title":"Long-term assessment of topiramate for epilepsy: An open-label, single-arm, multicentre, prospective study in a naturalistic setting; janssen Cilag (Germany)","volume":"31","author":"Hufnagel","year":"2011","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.yebeh.2022.108693_b2090","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1528-1167.2008.01584.x","article-title":"Topiramate in older patients with partial-onset seizures: A pilot double-blind, dose-comparison study","volume":"49","author":"Ramsay","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b2095","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/jcp.0b013e31815a43ee","article-title":"A randomized, double-blind, placebo-controlled trial of augmentation topiramate for chronic combat-related posttraumatic stress disorder","volume":"27","author":"Lindley","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b2100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WNF.0b013e318225140c","article-title":"Zonisamide versus topiramate in migraine prophylaxis: A double-blind randomized clinical trial","volume":"34","author":"Mohammadianinejad","year":"2011","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b2105","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ejpn.2014.07.005","article-title":"Safety and tolerability of zonisamide in paediatric patients with epilepsy","volume":"18","author":"Cross","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2110","first-page":"45","article-title":"The efficacy and safety of zonisamide as an add-on drug in the treatment of lennox-gastaut syndrome","volume":"4","author":"Fallah","year":"2010","journal-title":"Iran J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2115","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107139","article-title":"Treatment of status epilepticus with zonisamide: A multicenter cohort study of 34 patients and review of literature","volume":"109","author":"Hubert","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b2120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/0920-1211(93)90011-U","article-title":"Zonisamide for add-on treatment of refractory partial epilepsy: A European double-blind trial; Parke Davis (Germany)","volume":"15","author":"Schmidt","year":"1993","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b2125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.yebeh.2010.01.016","article-title":"A prospective audit of adjunctive zonisamide in an everyday clinical setting","volume":"17","author":"Stephen","year":"2010","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2022.108693_b2130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1212\/WNL.60.1.147","article-title":"Zonisamide-induced restless legs syndrome","volume":"60","author":"Chen","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b2135","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/mds.21449","article-title":"Restless legs syndrome induced by zonisamide [4]","volume":"22","author":"Velasco","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.yebeh.2022.108693_b2140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/ane.12611","article-title":"Audit of use of stiripentol in adults with dravet syndrome","volume":"135","author":"Balestrini","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108693_b2145","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.eplepsyres.2015.03.012","article-title":"Long-term safety and efficacy of stiripentol for the treatment of dravet syndrome: A multicenter, open-label study in Japan","volume":"113","author":"Inoue","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b2150","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1528-1167.2009.02179.x","article-title":"Stiripentol open study in Japanese patients with Dravet syndrome","volume":"50","author":"Inoue","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b2155","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/dmcn.13704","article-title":"Stiripentol efficacy and safety in dravet syndrome: A 12-year observational study","volume":"60","author":"Myers","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2160","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1177\/0883073818811538","article-title":"Efficacy of stiripentol and the clinical outcome in dravet syndrome","volume":"34","author":"Y\u0131ld\u0131z","year":"2019","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2165","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ejpn.2012.10.009","article-title":"Are vigabatrin induced T2 hyperintensities in cranial MRI associated with acute encephalopathy and extrapyramidal symptoms?","volume":"17","author":"Dill","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2170","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/0140-6736(91)91557-B","article-title":"Reversible motor disturbances induced by vigabatrin [28]","volume":"338","author":"Jongsma","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.yebeh.2022.108693_b2175","doi-asserted-by":"crossref","first-page":"2S30","DOI":"10.1177\/0883073891006002071","article-title":"Vigabatrin in childhood epilepsy","volume":"6","author":"Dulac","year":"1991","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2180","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/dmcn.12188","article-title":"An investigation into the relationship between vigabatrin, movement disorders, and brain magnetic resonance imaging abnormalities in children with infantile spasms","volume":"55","author":"Fong","year":"2013","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2185","doi-asserted-by":"crossref","first-page":"113S","DOI":"10.1111\/j.1365-2125.1989.tb03471.x","article-title":"Vigabatrin in epilepsy in mentally retarded patients","volume":"27","author":"Matilainen","year":"1989","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b2190","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.38.5.743","article-title":"Effect of vigabatrin on epilepsy in mentally retarded patients: A 7-month follow-up study","volume":"38","author":"Matilainen","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b2195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.1992.tb05079.x","article-title":"Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy","volume":"86","author":"Tartara","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2022.108693_b2200","doi-asserted-by":"crossref","first-page":"2S38","DOI":"10.1177\/0883073891006002081","article-title":"Vigabatrin in pediatric epilepsy - an open study","volume":"6","author":"Uldall","year":"1991","journal-title":"J Child Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2205","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1528-1167.2006.00530.x","article-title":"Transient athetosis induced by tiagabine","volume":"47","author":"Tombini","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b2210","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1046\/j.1528-1157.2001.042007944.x","article-title":"Transient dystonias in three patients treated with tiagabine","volume":"42","author":"Wola\u0144czyk","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b2215","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: A multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2220","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.seizure.2012.09.015","article-title":"Rufinamide for refractory focal seizures: An open-label, multicenter European study","volume":"22","author":"Coppola","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b2225","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40120-016-0041-9","article-title":"Treatment of adults with Lennox-Gastaut syndrome: Further analysis of efficacy and safety\/tolerability of rufinamide; eisai","volume":"5","author":"McMurray","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1016\/j.yebeh.2022.108693_b2230","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/j.1528-1167.2009.02160.x","article-title":"Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: A randomized placebo-controlled trial","volume":"50","author":"Brodie","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b2235","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.pediatrneurol.2010.02.013","article-title":"Efficacy of felbamate in the treatment of intractable pediatric epilepsy","volume":"42","author":"Zupanc","year":"2010","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2240","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1212\/WNL.45.4.846","article-title":"Reversible downbeat nystagmus and ataxia in felbamate intoxication","volume":"45","author":"Hwang","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b2245","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1212\/WNL.45.1.185","article-title":"Involuntary movement disorders associated with felbamate","volume":"45","author":"Kerrick","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2022.108693_b2250","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ana.410210220","article-title":"Opsoclonus induced by phenytoin and diazepam","volume":"21","author":"Dehaene","year":"1987","journal-title":"Ann Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2255","first-page":"230","article-title":"Primidone\/phenobarbital-induced periodic alternating nystagmus","volume":"21","author":"Schwankhaus","year":"1989","journal-title":"Ann Ophthalmol"},{"key":"10.1016\/j.yebeh.2022.108693_b2260","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ebcr.2015.07.003","article-title":"Anticonvulsant-induced downbeat nystagmus in epilepsy","volume":"4","author":"Wu","year":"2015","journal-title":"Epilepsy Behav Case Report"},{"key":"10.1016\/j.yebeh.2022.108693_b2265","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1053\/seiz.2001.0555","article-title":"Anticonvulsants-induced chorea: A role for pharmacodynamic drug interaction?","volume":"10","author":"Zaatreh","year":"2001","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2022.108693_b2270","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pediatrneurol.2012.04.026","article-title":"Late adverse effects of the coadministration of valproate and lamotrigine","volume":"47","author":"Thome-Souza","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2275","doi-asserted-by":"crossref","first-page":"116601","DOI":"10.1016\/j.jns.2019.116601","article-title":"Efficacy upon 12-weeks after achievement of maximal dose and tolerability of lacosamide as an adjunctive therapy in epilepsy: Real world clinical experience","volume":"409","author":"Chang","year":"2020","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.yebeh.2022.108693_b2280","doi-asserted-by":"crossref","first-page":"e007711","DOI":"10.1136\/bmjopen-2015-007711","article-title":"Safety of lamotrigine in paediatrics: A systematic review","volume":"5","author":"Egunsola","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.yebeh.2022.108693_b2285","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1590\/S0004-282X2008000400007","article-title":"Association of lamotrigine and valproate in refractory epilepsies of children and adolescents","volume":"66","author":"Grisotto","year":"2008","journal-title":"Arq Neuro-Psiquiatr"},{"key":"10.1016\/j.yebeh.2022.108693_b2290","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00045391-199801000-00003","article-title":"Lack of pharmacokinetic drag interactions between tiagabine and carbamazepine or phenytoin","volume":"5","author":"Gustavson","year":"1998","journal-title":"Am J Ther"},{"key":"10.1016\/j.yebeh.2022.108693_b2295","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1528-1167.2008.01866.x","article-title":"Lamotrigine-valproic acid combination therapy for medically refractory epilepsy","volume":"50","author":"Moeller","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b2300","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2305","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/archneur.1994.00540200043014","article-title":"Cerebellar atrophy in patients with long-term phenytoin exposure and epilepsy","volume":"51","author":"Ney","year":"1994","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2310","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1528-1157.1985.tb05191.x","article-title":"Dopaminergic supersensitivity after long-term administration of phenytoin in rats","volume":"26","author":"Lalonde","year":"1985","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b2315","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40263-016-0341-8","article-title":"Valproate-associated parkinsonism: A critical review of the literature","volume":"30","author":"Brugger","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2022.108693_b2320","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0920-1211(97)00042-9","article-title":"Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus","volume":"28","author":"Okada","year":"1997","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2022.108693_b2325","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/BF00589904","article-title":"Effects of carbamazepine on dopamine function in rodents","volume":"99","author":"Elphick","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.yebeh.2022.108693_b2330","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1528-1157.1986.tb03579.x","article-title":"Effect of carbamazepine on dopamine release and reuptake in rat striatal slices","volume":"27","author":"Barros","year":"1986","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b2335","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0014-2999(97)83041-5","article-title":"Carbamazepine increases extracellular serotonin concentration: Lack of antagonism by tetrodotoxin or zero Ca2+","volume":"328","author":"Dailey","year":"1997","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b2340","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archneur.1994.00540180083018","article-title":"Serotonin and human myoclonus. rationale for the use of serotonin receptor agonists and antagonists","volume":"51","author":"Pranzatelli","year":"1994","journal-title":"Arch Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2345","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF01243384","article-title":"Gabapentin augments whole blood serotonin in healthy young men","volume":"73","author":"Rao","year":"1988","journal-title":"J Neural Transm"},{"key":"10.1016\/j.yebeh.2022.108693_b2350","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00210-007-0237-8","article-title":"Differential modulation of K(+)-evoked (3)H-neurotransmitter release from human neocortex by gabapentin and pregabalin","volume":"376","author":"Brawek","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.yebeh.2022.108693_b2355","first-page":"529","article-title":"5-HT-mediated myoclonus in the guinea pig as a model of brainstem 5-HT and tryptamine receptor action","volume":"43","author":"Luscombe","year":"1986","journal-title":"Adv Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2360","first-page":"577","article-title":"P, p'-DDT-induced myoclonus in the rat and its application as an animal model of 5-HT-sensitive action myoclonus","volume":"43","author":"Pratt","year":"1986","journal-title":"Adv Neurol"},{"key":"10.1016\/j.yebeh.2022.108693_b2365","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1528-1157.2000.tb02168.x","article-title":"Concentration-effect studies with topiramate on selected enzymes and intermediates of the GABA shunt","volume":"41","author":"Sills","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2022.108693_b2370","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/archopht.118.4.544","article-title":"Acquired nystagmus","volume":"118","author":"Stahl","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"Pt 5","key":"10.1016\/j.yebeh.2022.108693_b2375","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/brain\/113.5.1425","article-title":"Vestibular function in periodic alternating nystagmus","volume":"113","author":"Furman","year":"1990","journal-title":"Brain"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022001421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505022001421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:46:57Z","timestamp":1761504417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505022001421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":475,"alternative-id":["S1525505022001421"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108693","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Movement disorders associated with antiseizure medications: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2022.108693","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108693"}}